NASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis $4.16 +0.08 (+1.96%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.96▼$4.1750-Day Range$2.93▼$4.2552-Week Range$1.07▼$4.50Volume469,126 shsAverage Volume1.36 million shsMarket Capitalization$582.78 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mereo BioPharma Group alerts: Email Address Mereo BioPharma Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.20 Rating ScoreUpside/Downside80.5% Upside$7.50 Price TargetShort InterestHealthy2.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 3 Articles This WeekInsider TradingSelling Shares$576,214 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.37 out of 5 starsMedical Sector330th out of 936 stocksPharmaceutical Preparations Industry153rd out of 436 stocks 4.6 Analyst's Opinion Consensus RatingMereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMereo BioPharma Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mereo BioPharma Group's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.22% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mereo BioPharma Group has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MREO. Previous Next 2.5 News and Social Media Coverage News SentimentMereo BioPharma Group has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mereo BioPharma Group this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $576,214.00 in company stock.Percentage Held by InsidersOnly 4.13% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mereo BioPharma Group's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 11.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mereo BioPharma Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Mereo BioPharma Group Stock (NASDAQ:MREO)Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Read More MREO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MREO Stock News HeadlinesJune 29, 2024 | insidertrades.comMereo BioPharma Group plc (NASDAQ:MREO) Insider Sells $27,365.04 in StockJuly 22, 2024 | americanbankingnews.comMereo BioPharma Group's (MREO) Overweight Rating Reiterated at Cantor FitzgeraldJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 30, 2024 | seekingalpha.comMereo BioPharma: Positioned For Potential BreakthroughsJune 14, 2024 | globenewswire.comMereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-MarketMay 30, 2024 | globenewswire.comMereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare ConferenceMay 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)May 16, 2024 | finanznachrichten.deMereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 15, 2024 | globenewswire.comMereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 1, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday TradingMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)May 1, 2024 | markets.businessinsider.comStrong Buy Rating for Mereo Biopharma on Setrusumab’s Promising Phase 3 Progress and Financial OutlookApril 10, 2024 | seekingalpha.comMereo BioPharma's Pipeline Promise Vs. Valuation And Market RealitiesApril 3, 2024 | globenewswire.comMereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 27, 2024 | globenewswire.comMereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 16, 2024 | finance.yahoo.comMREO Apr 2024 3.500 putMarch 16, 2024 | ca.finance.yahoo.comMREO Aug 2024 5.500 callSee More Headlines Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MREO CUSIPN/A CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$8.00 Low Stock Price Target$7.00 Potential Upside/Downside+80.5%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.86 Quick Ratio4.86 Sales & Book Value Annual Sales$10 million Price / Sales58.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book11.54Miscellaneous Outstanding Shares140,260,000Free Float134,464,000Market Cap$582.78 million OptionableOptionable Beta0.88 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Denise Vera Scots-Knight Ph.D. (Age 65)Co-Founder, CEO & Executive Director Comp: $890.56kMr. Charles Edward Sermon (Age 55)Co-Founder, General Counsel, Business Development & Company Secretary Comp: $625.79kMs. Christine Fox CPA (Age 43)Chief Financial Officer Comp: $569.77kDr. John P. Richard M.B.A. (Age 67)Co-Founder & Chief Business Officer Dr. John A. Lewicki Ph.D. (Age 72)Chief Scientific Officer Dr. Jackie Parkin (Age 66)Senior VP & Therapeutic Head Ms. Alexandra Hughes-Wilson (Age 53)Chief of Patient Access & Commercial Planning Dr. Suba Krishnan (Age 59)Senior Vice President of Clinical Development Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMCMore ExecutivesKey CompetitorsAmneal PharmaceuticalsNASDAQ:AMRXRocket PharmaceuticalsNASDAQ:RCKTProtagonist TherapeuticsNASDAQ:PTGXDeciphera PharmaceuticalsNASDAQ:DCPHMaravai LifeSciencesNASDAQ:MRVIView All CompetitorsInsiders & InstitutionsDenise Scots-KnightSold 40,712 sharesTotal: $150,227.28 ($3.69/share)Charles SermonSold 14,202 sharesTotal: $52,405.38 ($3.69/share)Christine Ann FoxSold 12,990 sharesTotal: $47,933.10 ($3.69/share)John A LewickiSold 7,416 sharesTotal: $27,365.04 ($3.69/share)Alexandra Hughes-WilsonSold 100,432 sharesTotal: $298,283.04 ($2.97/share)View All Insider TransactionsView All Institutional Transactions MREO Stock Analysis - Frequently Asked Questions How have MREO shares performed this year? Mereo BioPharma Group's stock was trading at $2.31 at the beginning of 2024. Since then, MREO stock has increased by 79.9% and is now trading at $4.1550. View the best growth stocks for 2024 here. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc (NASDAQ:MREO) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.01) EPS for the quarter. When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). This page (NASDAQ:MREO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.